Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPHW) Sees Large Decrease in Short Interest

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPHW) was the target of a significant drop in short interest in February. As of February 28th, there was short interest totalling 2,300 shares, a drop of 36.1% from the February 13th total of 3,600 shares. Based on an average daily volume of 43,900 shares, the short-interest ratio is currently 0.1 days.

Reviva Pharmaceuticals Price Performance

Shares of RVPHW stock traded down $0.00 during trading hours on Friday, hitting $0.06. 89,456 shares of the company’s stock traded hands, compared to its average volume of 33,273. The stock’s fifty day simple moving average is $0.16 and its two-hundred day simple moving average is $0.16. Reviva Pharmaceuticals has a 12-month low of $0.04 and a 12-month high of $0.78.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis.